Search clinical trials for: LY2216684 (edivoxetine)

Total 29 results

Eli Lilly and Company

Terminated

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States, Canada, Taiwan, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2216684 in Participants With Impaired Hepatic Function

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Healthy Participants

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Safety Study in Participants With Major Depressive Disorder

Depressive Disorder, Major

United States, Mexico, Spain, Brazil, Chile, Lithuania, Netherlands
Eli Lilly and Company

Completed

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Major Depressive Disorder

United Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Food on LY2216684

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
Eli Lilly and Company

Completed

A Study in Adult Patients With Major Depressive Disorder

Depressive Disorder, Major

United States, Finland, Poland, Russian Federation, Argentina
Eli Lilly and Company

Completed

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Major Depressive Disorder (MDD)

United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
Eli Lilly and Company

Completed

A Study in Prevention of Re-emergence of Depression Symptoms

Major Depressive Disorder

United States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
Eli Lilly and Company

Completed

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States, Canada, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Participants With Major Depression Disorder

Major Depressive Disorder

Japan
Eli Lilly and Company

Completed

A Study for Participants With Major Depression

Major Depressive Disorder

United States, Romania
Eli Lilly and Company

Completed

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Warfarin in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Digoxin in Healthy Subjects

Major Depressive Disorder

United States
Tasly Pharmaceuticals, Inc.

Completed

Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA)

Angina Pectoris

Canada, United States, Russian Federation, Belarus, Georgia, Mexico, Ukraine
Eli Lilly and Company

Completed

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Theophylline in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of the Effect of LY2216684 on Lorazepam

Major Depressive Disorder

United Kingdom
Eli Lilly and Company

Completed

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Healthy Females

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Genotype on LY2216684

Depressive Disorder, Major

United States
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States

Search clinical trials for: LY2216684 (edivoxetine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations